Business context and reporting period
Issuer mismatch: The supplied filing is Sigma Labs, Inc.’s Form 10-K, not a Nexttrip, Inc. filing. It reports the fiscal year ended December 31, 2011, compared with 2010; it is not a quarterly filing. Sigma Labs develops manufacturing and materials technologies, including in-process quality assurance (IPQA), and earns revenue primarily from consulting. On December 31, 2011, it acquired Sumner and La Mancha for 35 million shares; their 2011 operating results were excluded from reported results.
Financial performance and position
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $797,354 | $498,504 |
| Gross profit / margin | $384,958 / 48.3% | $391,441 / 78.5% |
| Operating expenses | $1,296,200 | $801,387 |
| Net loss | $(910,129) | $(421,946) |
| Operating cash flow | $(575,469) | $(528,236) |
| Cash at year-end | $653,113 | $226,268 |
Revenue rose about 60%, but gross profit fell and gross margin contracted as cost of services increased to $412,396 from $107,063. The larger net loss reflected higher payroll and non-cash stock compensation, among other expenses. Basic and diluted loss per share was reported as $(0.00) in both years.
At December 31, 2011, current assets were $945,281 and current liabilities $174,702, yielding reported working capital of $770,579. Total liabilities were $174,702, consisting of accounts payable and accrued expenses; no debt was reported on the balance sheet. Stockholders’ equity was $1,101,494. The company raised $1,011,765 net from a 2011 private stock offering. Cash increased by $426,845 during the year, supported by financing inflows despite operating cash use.
Material changes and unusual items
- Sumner and La Mancha were acquired for stock valued at $350,000. Their results were not included in the reported FY 2011 income statement; unaudited pro forma combined revenue and net loss were $1,899,773 and $(935,439), respectively.
- Revenue remained concentrated: one unnamed customer represented 53% of FY 2011 revenue and another 12%. The filing’s customer-concentration note does not identify these customers by name.
- Management reported a material weakness in internal control over financial reporting involving restricted-stock compensation accounting. Interim-period expenses and net loss had been overstated by $303,000; management said the weakness had been remedied. The auditor did not attest to internal controls.
- At year-end, 429,667,400 common shares were outstanding, compared with 313,067,400 a year earlier. The 2011 private placement and acquisition were significant sources of share issuance.
Outlook, risks and contingencies
Management expected to pursue commercialization of IPQA and munitions technologies during 2012 and continue developing dental implant technology. No formal financial guidance was provided. Management said it expected sufficient 2012 funds based on cash, consulting contracts and anticipated securities proceeds, but emphasized that funding needs remained dependent on consulting revenue and additional financing. As of March 31, 2012, the company cited potential 2012 revenue of up to $158,227 from B6 Sigma contracts and $580,100 from Sumner contracts; La Mancha had no active contracts. These are contract expectations, not reported revenue or guaranteed results.
The auditor expressed substantial doubt about the company’s ability to continue as a going concern, citing limited revenue and the absence of profitable operations. Key risks include continued losses and need for capital, possible dilution, dependence on consulting and government contracts, customer concentration, fixed-price contract cost overruns, commercialization and patent risks, and government-contracting compliance. Management also disclosed weak disclosure controls and no CFO; senior executives reduced or suspended salaries beginning in 2012 as a cost-saving measure. The filing reported no current legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the provided document identifies Sigma Labs, Inc., not Nexttrip, Inc.
- Review the audited statements, going-concern note, and financing needs; the filing provides no assurance that anticipated financing or profitability will materialize.
- Verify the status and revenue contribution of the acquired businesses and the active contracts cited for 2012.
- Assess customer concentration, the interim-period compensation-control error, and whether the stated control remediation was sustained.
- Check dilution, share issuance and market liquidity; the filing describes the OTC-traded stock as thinly traded and reports 429,667,400 shares outstanding as of March 30, 2012.
- Treat commercialization timelines and additive-manufacturing revenue estimates as forward-looking management expectations, not realized results.